NOVARTIS

DelveInsight's report on KRAS Inhibitors covers market trends, epidemiology, and pipeline developments in the US, EU4, UK, and Japan. The market is driven by cancer incidence and personalized treatments, with key companies like Novartis, Roche, and Verastem Oncology leading in KRAS inhibitor therapies.

Eli Lilly's muvalaplin, an oral cholesterol-lowering drug, significantly reduced Lp(a) levels in a 12-week phase II study, meeting primary and secondary endpoints. Muvalaplin disrupts apolipoprotein(a) and apolipoprotein(b) interaction, potentially reducing cardiovascular risk. Lilly's stock has risen 24.7% this year.

C Ray Therapeutics, a radiopharmaceutical innovator, secured over $100 million in Series A+ financing, co-led by SCGC and TaiLong Capital, to enhance core tech platforms, accelerate R&D pipelines, and improve global patient treatment options.

Zerlasiran, an siRNA, reduced time-averaged Lp(a) concentrations by over 80% in a 36-week trial, marking the first time such reduction has been reported for an siRNA therapy. The study suggests that each successive dose of zerlasiran extends the duration of Lp(a) reduction, informing future phase 3 trials and potentially optimal dosing strategies for other siRNA therapies.

Astellas' request to update Izervay's prescribing info rejected by FDA; Jupiter Bioventures, co-founded by Norman Sharpless and Nathaniel David, launches with $70M to create biotech startups; Bayer pays Cytokinetics $53M for aficamten licensing in Japan; Neurogene continues Rett syndrome gene therapy trial at lowest dose after side effects; Cybin's stock dips despite positive Phase 2 data for CYB003; Novartis licenses radiopharmaceutical from Ratio Therapeutics, targeting SSTR2 protein.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.

The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.

Novartis ranks first in the 2024 Access to Medicine Index, highlighting its leadership in research, development, and governance of access, with best practices in malaria access plans and product registration in LMICs.

Gender bias in cardiac treatment guidelines puts women at risk due to underrepresentation in clinical trials. Syndax Pharmaceuticals receives FDA approval for Revuforj in leukemia. Biosion sells antibody rights to Aclaris for $940M. Novartis expands radiopharma with $745M Ratio deal. Arbutus Biopharma presents promising hepatitis B cure data. Neurogene faces safety concerns with Rett syndrome gene therapy. Keymed out-licenses bispecific antibody CM-336 to Platina for $626M. Biopharma deal value surges 72% in October. China's biopharmaceutical sector sees growth driven by policy reforms. BioWorld Insider podcast features Modifi Biosciences' journey to acquisition.

Two new drugs, an siRNA and an oral agent, reduced Lp(a) by 80% in phase II studies. Zerlasiran, the siRNA, lowered Lp(a) by 85% over 36 weeks, while muvalaplin, the oral agent, reduced Lp(a) by 70% with a traditional assay and over 85% with an intact assay. Both therapies offer potential for treating cardiovascular disease, with muvalaplin providing an oral alternative to injectables.